A number of firms have modified their ratings and price targets on shares of Valeant Pharmaceuticals Intl (NYSE: VRX) recently:

  • 10/22/2017 – Valeant Pharmaceuticals Intl was given a new $14.00 price target on by analysts at Piper Jaffray Companies. They now have a “sell” rating on the stock.
  • 10/20/2017 – Valeant Pharmaceuticals Intl had its price target lowered by analysts at Royal Bank Of Canada from $21.00 to $18.00. They now have a “sector perform” rating on the stock.
  • 10/19/2017 – Valeant Pharmaceuticals Intl was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $14.26 price target on the stock.
  • 10/13/2017 – Valeant Pharmaceuticals Intl was downgraded by analysts at Vetr from a “strong-buy” rating to a “hold” rating. They now have a $14.26 price target on the stock.
  • 10/12/2017 – Valeant Pharmaceuticals Intl was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Once an acquisition giant, Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services. After a tumultuous period, Valeant started a rebuilding process with its new CEO, Joseph C. Papa. Even though it is still early to comment on the rebuilding process, but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable. The company reduced its debt by $4.8 billion and expects to meet its target of $5 billion debt reduction ahead of schedule. The GI business continues to struggle with weak sales of Xifaxan but should see gain in market share with an increased sales force. Valeant trimmed its guidance due to recent divestitures. However, weakness in the dermatology business persists. Shares have underperformed the industry.”
  • 10/9/2017 – Valeant Pharmaceuticals Intl had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $18.00 price target on the stock.
  • 10/6/2017 – Valeant Pharmaceuticals Intl was upgraded by analysts at Vetr from a “strong sell” rating to a “sell” rating. They now have a $13.68 price target on the stock.
  • 10/4/2017 – Valeant Pharmaceuticals Intl had its “hold” rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
  • 10/3/2017 – Valeant Pharmaceuticals Intl had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $16.00 price target on the stock.
  • 10/2/2017 – Valeant Pharmaceuticals Intl was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/30/2017 – Valeant Pharmaceuticals Intl had its “underperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $8.00 price target on the stock.
  • 9/28/2017 – Valeant Pharmaceuticals Intl was upgraded by analysts at Vetr from a “strong sell” rating to a “sell” rating. They now have a $12.46 price target on the stock.
  • 9/28/2017 – Valeant Pharmaceuticals Intl had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $23.00 price target on the stock.
  • 9/25/2017 – Valeant Pharmaceuticals Intl had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $19.00 price target on the stock.
  • 9/18/2017 – Valeant Pharmaceuticals Intl was upgraded by analysts at Vetr from a “strong sell” rating to a “sell” rating. They now have a $12.46 price target on the stock.
  • 9/18/2017 – Valeant Pharmaceuticals Intl had its “hold” rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
  • 9/17/2017 – Valeant Pharmaceuticals Intl had its “sell” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $14.00 price target on the stock.
  • 9/12/2017 – Valeant Pharmaceuticals Intl was downgraded by analysts at Vetr from a “sell” rating to a “strong sell” rating. They now have a $12.46 price target on the stock.
  • 9/1/2017 – Valeant Pharmaceuticals Intl was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/29/2017 – Valeant Pharmaceuticals Intl had its “sell” rating reaffirmed by analysts at Mizuho. They now have a $7.00 price target on the stock, down previously from $8.00.
  • 8/29/2017 – Valeant Pharmaceuticals Intl had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $23.00 price target on the stock.
  • 8/24/2017 – Valeant Pharmaceuticals Intl was downgraded by analysts at Vetr from a “strong-buy” rating to a “sell” rating. They now have a $13.30 price target on the stock.

Valeant Pharmaceuticals Intl Inc (NYSE VRX) traded up 0.0289% during mid-day trading on Monday, hitting $12.1335. The company had a trading volume of 2,277,421 shares. The company has a 50 day moving average of $13.81 and a 200 day moving average of $13.59. Valeant Pharmaceuticals Intl Inc has a 1-year low of $8.31 and a 1-year high of $24.30. The firm’s market capitalization is $4.23 billion.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. The company had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals Intl had a negative net margin of 1.66% and a negative return on equity of 3.90%. Valeant Pharmaceuticals Intl’s revenue for the quarter was down 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.88) earnings per share. Analysts predict that Valeant Pharmaceuticals Intl Inc will post $3.89 earnings per share for the current fiscal year.

In other Valeant Pharmaceuticals Intl news, Director Schutter Richard U. De acquired 10,000 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Monday, August 21st. The stock was bought at an average price of $14.33 per share, with a total value of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.